Gastro Intestinal Stromal Tumor: State of the Art through Our Experience of 64 Cases and a Literature Review

Slaiki, Saad; Bouhaddouti, Hicham El; Ousadden, Abdelmalek; Taleb, Khalid Ait; Benjelloun, El Bachir

doi:10.4236/jct.2020.115022

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathological manifestations are spindle cells or epithelioid cells, and the histochemical characteristics are that the tumor is CD117, CD34, and DOG1 positive [1][2][3]. Due to the diversity and complexity of the biological behavior of GIST, it cannot be classified solely as benign or malignant; the risk of GIST biological behavior can be quickly and effectively judged by examining the patient's treatment plan and prognosis, as it is closely related to these [4,5]. 18 F-FDG metabolic imaging reflects the level of glucose metabolism of tumors, which is positively correlated with the risk of the tumors [6,7].…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of 18F-FDG PET/CT imaging in 32 cases of gastrointestinal stromal tumors

et al. 2022

View full text Add to dashboard Cite

Objectives To explore the clinical significance of 18F-FDG metabolic imaging in the diagnosis and biological risk assessment of gastrointestinal stromal tumors (GIST). Methods This study is a clinical retrospective study. The research subjects were patients with GIST who were admitted to our hospital from January 2014 to December 2019 and underwent 18F-FDG metabolic imaging, and the relationship between biological risk and FDG metabolism was analyzed retrospectively. Results A total of 32 patients with GIST were included in this study, of which 17 patients had very low and low-risk lesions, and the FDG metabolism level did not increase; five patients had moderate-risk gastric lesions, and the FDG metabolism level was abnormally increased; 10 patients had high-risk lesions, and except for one patient with multiple lesions, the FDG metabolism level of these patients was increased. Conclusions The level of glucose metabolism is abnormally increased in tumor cells with vigorous mitosis and has higher biological risk. The 18F-FDG metabolism level can determine the biological risk of GIST and whether high-risk lesions involve other tissues and organs, as it more comprehensively reflects the distribution of lesions, the activity of tumor cells and the stage of the disease.

show abstract